Henderson Lindsay M, Claw Katrina G, Woodahl Erica L, Robinson Renee F, Boyer Bert B, Burke Wylie, Thummel Kenneth E
Departments of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
J Pers Med. 2018 Feb 1;8(1):9. doi: 10.3390/jpm8010009.
Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.
北美原住民群体,包括美国的美洲印第安人和阿拉斯加原住民、加拿大的第一民族、梅蒂斯人和因纽特人以及墨西哥的美洲印第安人,在生物医学研究中,包括药物处置和反应的基因组研究中,历史上代表性不足。在建立基因型 - 表型关系的药物遗传学研究中,如果没有足够的代表性,原住民群体可能无法充分受益于精准医学检测的新创新,以定制和提高药物治疗的安全性和有效性,从而导致医疗保健差距。本综述的目的是总结和评估目前关于北美原住民群体细胞色素基因变异的已知情况,并强调在未来的药物遗传学研究中纳入这些群体以实施个性化药物治疗的重要性。